 The development of direct acting antivirals to combat COVID-19 remains an important goal. Here the authors design covalent inhibitors that target the papain-like proteins from SARS-CoV-2. The most promising inhibitor blocks viral replication in mammalian cells. This article was authored by Brian C. Sanders, Suman Pockel, Audrey D. Lab and others.